Evidence map›Paper›PMID 37267953›Full record

ArticleCancer cell2023

Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer.

Scott Haston, Estela Gonzalez-Gualda, Samir Morsli, Jianfeng Ge, Virinder Reen, Alexander Calderwood, Ilias Moutsopoulos, Leonidas Panousopoulos, Polina Deletic, Gabriela Carreno and 18 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 2 pooled it
35.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 2 syntheses or guidelines pooled it, 211 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Terpenoids as modulators of autophagy-senescence crosstalk in lung cancer.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  6. The immunology behind inflammaging-causes, sources, and mechanisms.The Journal of allergy and clinical immunology · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 10 institutions in 2 countries.

Scott HastonDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK. Electronic address: scott.haston.13@ucl.ac.uk.
Estela Gonzalez-GualdaEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Samir MorsliEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Jianfeng GeEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Virinder ReenMRC London Institute of Medical Sciences (LMS), Du Cane Road, London W12 0NN, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK.
Alexander CalderwoodWellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK.
Ilias MoutsopoulosWellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK.
Leonidas PanousopoulosDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK.
Polina DeleticDivision of Medicine, University College London, London, UK.
Gabriela CarrenoDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK.
Romain GuihoDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK.
Saba ManshaeiDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK.
Jose Mario Gonzalez-MeljemTecnologico de Monterrey, School of Engineering and Sciences, Mexico City, Mexico.
Hui Yuan LimDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK.
Daniel J SimpsonMRC Human Generics Unit, University of Edinburgh, Edinburgh, UK.
Jodie BirchMRC London Institute of Medical Sciences (LMS), Du Cane Road, London W12 0NN, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK.
Husayn A PallikondaMRC London Institute of Medical Sciences (LMS), Du Cane Road, London W12 0NN, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK.
Tamir ChandraMRC Human Generics Unit, University of Edinburgh, Edinburgh, UK.
David MaciasEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Gary J DohertyCambridge University Hospitals NHS Foundation Trust, Department of Oncology, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Doris M RasslRoyal Papworth Hospital NHS Foundation Trust. Cambridge Biomedical Campus, Cambridge CB2 0AY, UK.
Robert C RintoulRoyal Papworth Hospital NHS Foundation Trust. Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Oncology, University of Cambridge, Cambridge, UK; CRUK Cambridge Centre Thoracic Cancer Programme, Cambridge, UK.
Massimo SignoreDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK.
Irina MohorianuWellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK.
Arne N AkbarDivision of Medicine, University College London, London, UK.
Jesús GilMRC London Institute of Medical Sciences (LMS), Du Cane Road, London W12 0NN, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK.
Daniel Muñoz-EspínEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK; CRUK Cambridge Centre Thoracic Cancer Programme, Cambridge, UK. Electronic address: dm742@cam.ac.uk.
Juan Pedro Martinez-BarberaDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK. Electronic address: j.martinez-barbera@ucl.ac.uk.
University College London · GBUniversity of Cambridge · GBImperial College London · GBUniversity of Edinburgh · GBCancer Research UK Cambridge Center · GBWellcome/MRC Cambridge Stem Cell Institute · GBAddenbrooke's Hospital · GBMRC London Institute of Medical Sciences · GBPapworth Hospital NHS Foundation Trust · GBTecnológico de Monterrey · MX

Funding

Cancer Research UK 26989Cancer Research UK 27727Cancer Research UK 28647Cancer Research UK 29760Cancer Research UK C15075/A28647Cancer Research UK C54322/A27727Cancer Research UK C62187/A26989Cancer Research UK C62187/A29760Cancer Research UK C9685/A25117Cancer Research UK RG86786Department of HealthDepartment of Health BRC-1215-20014Medical Research Council MC_U120085810Medical Research Council MR/R000530/1Medical Research Council MR/T030534/1
6 · The paper itself

Abstract

The accumulation of senescent cells in the tumor microenvironment can drive tumorigenesis in a paracrine manner through the senescence-associated secretory phenotype (SASP). Using a new p16-FDR mouse line, we show that macrophages and endothelial cells are the predominant senescent cell types in murine KRAS-driven lung tumors. Through single cell transcriptomics, we identify a population of tumor-associated macrophages that express a unique array of pro-tumorigenic SASP factors and surface proteins and are also present in normal aged lungs. Genetic or senolytic ablation of senescent cells, or macrophage depletion, result in a significant decrease in tumor burden and increased survival in KRAS-driven lung cancer models. Moreover, we reveal the presence of macrophages with senescent features in human lung pre-malignant lesions, but not in adenocarcinomas. Taken together, our results have uncovered the important role of senescent macrophages in the initiation and progression of lung cancer, highlighting potential therapeutic avenues and cancer preventative strategies.

Indexed as

Cellular SenescenceLung NeoplasmsAgedAnimalsCarcinogenesisEndothelial CellsHumansMacrophagesMiceProto-Oncogene Proteins p21(ras)Tumor MicroenvironmentHras protein, mouseKRAS protein, humanProto-Oncogene Proteins p21(ras)ABT-737agingcancerendothelial cellsimmunosuppressionmacrophagesNSCLCp16INK4asenescencesenolytic

Identifiers

PMID37267953
OpenAlexW4379056388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.